Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | GABRP | O00591 | 2/20 | 0.33 |
| ▸ | GABRD | O14764 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.33 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.33 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.33 |
| ▸ | GABRE | P78334 | 2/20 | 0.33 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.33 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.33 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16786175 | 1.00 | ALDH1A1 (0.47) | ALDH1A1TDP1LMNASLC15A2CA1 | |
| SCHEMBL16360132 | 1.00 | ALDH1A1 (0.47) | ALDH1A1TDP1LMNASLC15A2CA1 | |
| SCHEMBL9720153 | 0.88 | ALDH1A1 (0.53) | ALDH1A1TDP1LMNASLC15A2CA1 | |
| SCHEMBL1783594 | 0.84 | ALDH1A1 (0.43) | ALDH1A1TDP1LMNASLC15A2CA1 | |
| SCHEMBL1781677 | 0.82 | PAOX (0.44) | ALDH1A1TDP1LMNASLC15A2ACHE | |
| SCHEMBL1783331 | 0.79 | ALDH1A1 (0.43) | ALDH1A1TDP1LMNASLC15A2CA1 | |
| SCHEMBL1783542 | 0.79 | ALDH1A1 (0.43) | ALDH1A1TDP1LMNASLC15A2CA1 | |
| SCHEMBL15943069 | 0.79 | ALDH1A1 (0.43) | ALDH1A1TDP1LMNASLC15A2CA1 | |
| SCHEMBL244922 | 0.78 | GABRP (0.56) | LMNAGABRPGABRDGABRA1GABRB1 | |
| SCHEMBL11802464 | 0.78 | ALDH1A1 (0.47) | ALDH1A1TDP1LMNASLC15A2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110590523-A | Synthesis method of cryptone | 天津市安凯特科技发展有限公司 | 2019-12-20 | — | — | CN | claimed |
| EP-2904080-B1 | FLAVOR AND FRAGRANCE FORMULATION (I) | DSM IP ASSETS BV (NL) | 2018-12-12 | — | — | EP | claimed |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| CN-110590523-A | Synthesis method of cryptone | 天津市安凯特科技发展有限公司 | 2019-12-20 | — | — | CN | disclosed |
| CN-110590523-A | Synthesis method of cryptone | 天津市安凯特科技发展有限公司 | 2019-12-20 | — | — | CN | disclosed |
| EP-2904080-B1 | FLAVOR AND FRAGRANCE FORMULATION (I) | DSM IP ASSETS BV (NL) | 2018-12-12 | — | — | EP | disclosed |
| US-9809824-B2 | CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170174877-A1 | COMPATIBILIZER AND THERMOPLASTIC RESIN EMPLOYING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2017-06-22 | — | — | US | disclosed |
| US-9428541-B2 | Substrate reduction therapy | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150307439-A1 | FLAVOR AND FRAGRANCE FORMULATION (I) | DSM IP ASSETS B.V. (NL) | 2015-10-29 | — | — | US | disclosed |
| US-20150307439-A1 | FLAVOR AND FRAGRANCE FORMULATION (I) | DSM IP ASSETS B.V. (NL) | 2015-10-29 | — | — | US | disclosed |
| WO-2009123355-A2 | COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2009-10-08 | — | — | WO | disclosed |
| EP-1737881-B1 | NOVEL COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS NS3 SERINE PROTEASE | SCHERING CORP (US) | 2009-06-24 | — | — | EP | disclosed |
| US-20090048226-A1 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-7358273-B2 | Inhibitors of caspases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070281308-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDE PRIMERS FOR NUCLEIC ACID AMPLIFICATION | TRILINK BIOTECHNOLOGIES, LLC | 2007-12-06 | — | — | US | disclosed |
| US-7186782-B2 | Hydrogenation catalyst composition and process for hydrogenation of conjugated diene polymer | TSRC CORPORATION (TW) | 2007-03-06 | — | — | US | disclosed |
| US-20060041079-A1 | Hydrogenation catalyst composition and process for hydrogenation of conjugated diene polymer | TSRC CORPORATION | 2006-02-23 | — | — | US | disclosed |
| US-6881797-B2 | Process for hydrogenation of conjugated diene polymer | TSRC CORPORATION (TW) | 2005-04-19 | — | — | US | disclosed |
| US-20040082727-A1 | Process for hydrogenation of conjugated diene polymer | TSRC CORPORATION (CN) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281308-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDE PRIMERS FOR NUCLEIC ACID AMPLIFICATION | POLRMT, POLI, POLM | ALDH1A1 384/4885TDP1 389/4885LMNA 1287/4885 |
| US-20150307439-A1 | FLAVOR AND FRAGRANCE FORMULATION (I) | NISCH, TAS2R5, FDFT1 | ALDH1A1 97/4885TDP1 4077/4885LMNA 3428/4885 |
| US-20090048226-A1 | Inhibitors of caspases | CASP1, APAF1, IRF3 | ALDH1A1 1431/4885TDP1 550/4885LMNA 613/4885 |
| US-20230159504-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINB1, SERPINE1 | ALDH1A1 542/4885TDP1 786/4885LMNA 1470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.